1. Introduction {#s0005}
===============

The toxicity experienced by women with early breast cancer undergoing adjuvant chemotherapy concerns both patients and clinicians, especially when more intensive, toxic regimens result in small or no overall survival gains. In meta-analyses of randomised controlled trials [@b0005] comparing taxane-containing chemotherapy with control regimens of similar duration, results showed no statistically significant reduction in the risk of recurrence (relative risk (RR): 0.96, standard error (SE):0.05; *p* \> 0.1) or death (RR: 0.96, SE: 0.06; *p* \> 0.1). These analyses were heavily influenced by the UK Taxotere® as Adjuvant Chemotherapy Trial (TACT, CRUK/01/001, ISRCTN79718493) [@b0010] which, with median 62 months follow-up, did not demonstrate an overall gain in disease-free (hazard ratio (HR): 0.95, 95% CI: 0.85--1.08) or overall survival (HR: 0.99 (0.86--1.14)). In this context the prospective assessment of patient reported toxicity and quality of life (QL) incorporated in TACT is particularly important although its relevance extends to other clinical scenarios where a small incremental benefit for taxane based regimens has been seen [@b0005].

The impact of adjuvant chemotherapy on QL is widely recognised. However, the assessment of taxane toxicity in breast cancer clinical trials has been based largely on clinical assessments [@b0010; @b0015; @b0020; @b0025; @b0030; @b0035; @b0040; @b0045; @b0050] and considered 'acceptable' [@b0025], 'tolerable' [@b0015] or 'manageable' [@b0045] when it is known that some clinicians' ratings of key symptoms and distress may not reflect those of patients [@b0055; @b0060; @b0065; @b0070]. Nevertheless, health professionals increasingly acknowledge that differences in toxicity profiles potentially influence choice of adjuvant treatment [@b0015], and that there is a need to improve the QL of patients receiving taxanes and better identify those more likely to benefit from treatment, to justify the trade off with toxicity [@b0030; @b0035; @b0040]. Others have argued that toxicity is transient and some women may accept acute toxicity for the chance of a small survival benefit [@b0075; @b0080]. However, longer term effects from chemotherapy, such as hot flushes, amenorrhoea and sexual dysfunction have also been consistently reported [@b0085], especially following a menopausal transition [@b0090]. Patient preferences are highly variable and so discussion of treatment options should be informed by patient reported outcomes of the impact of treatment on QL so that expectations are realistic. In an era where the duration of adjuvant therapy and/or accompanying toxicity has increased, even 'transient' treatment effects can extend over 6 months.

The TACT QL sub-study provides a randomised comparison of patient evaluated treatment related side effects in terms of severity, distress and disruption as well as the impact on a range of QL parameters, during treatment and over 6 years follow-up.

2. Methods {#s0010}
==========

2.1. Patients {#s0015}
-------------

Details of the TACT trial patient population, treatment regimens and procedures were previously reported [@b0010]. Briefly, women with operable invasive breast cancer who had undergone complete tumour excision and were to be prescribed adjuvant chemotherapy were eligible. Participating centres chose at the outset of the trial whether to participate in the QL sub-study. To minimise bias, centres were encouraged to offer the QL sub-study to all TACT patients able to read and understand English. Specific informed consent for the QL sub-study was obtained.

2.2. Procedures {#s0020}
---------------

### 2.2.1. Treatment {#s0025}

Women were randomised to receive fluorouracil~600~/epirubicin~60~/cyclophosphamide~600~ for four cycles followed by docetaxel~100~ for four cycles (FEC-D) or one of two standard regimens (choice declared by each centre at trial outset): F~600~E~60~C~600~ for eight cycles (FEC) or epirubicin~100~ for four cycles followed by cyclophosphamide~600x2~/methotrexate~40x2~/fluorouracil~600x2~ for four cycles (E-CMF) [@b0095]. Women receiving E-CMF had a slightly longer overall duration of treatment as CMF was given over four-weekly cycles (all other cycles given over three weeks). Following chemotherapy, tamoxifen was prescribed for 5 years in patients with oestrogen receptor and/or progesterone receptor positive tumours, or (from 2005) an aromatase inhibitor could be prescribed according to local policy. Radiotherapy commencing within four weeks of completion of chemotherapy was mandatory after breast conserving surgery and according to local clinical guidelines following mastectomy.

### 2.2.2. QL assessments {#s0030}

Consenting women completed a baseline QL questionnaire booklet, administered by their hospital team in the outpatient clinic, before randomisation. Subsequent booklets were mailed by ISD Cancer Clinical Trials Unit Scotland (CaCTUS) for completion at home (after checking the individual's health status with their hospital team or family doctor), after cycles 4 and 8 of chemotherapy, then at 9, 12, 18 and 24 months. A single prompt was made if booklets were not returned within 8 weeks.

QL was evaluated using the EORTC (European Organisation for the Research and Treatment of Cancer) general cancer scale QLQ-C30 [@b0100] and breast cancer module, BR23 [@b0105]. The QLQ-C30 comprises five functional subscales (physical, role, emotional, cognitive, social), three symptom subscales (fatigue, nausea/vomiting, pain), five symptom items and one item reporting financial difficulties. Questionnaire items had a 4-point response format (not at all, a little, quite a bit, very much). Two items captured global health and global QL, each rated on a 7-point numeric scale. The BR23 comprises four functional subscales/items (body image, sexual functioning, sexual enjoyment, future perspective) and four symptom subscales/items including systemic side effects. Anxiety and depression were measured using the Hospital Anxiety and Depression Scale (HADS) [@b0110].

A trial specific patient self-report diary (see [web appendix](#s0110){ref-type="sec"}) was constructed and piloted, based on a prototype developed for cancer trials [@b0115; @b0120]. Patients rated the extent to which side effects of anthracycline and taxane-based chemotherapy were experienced (rated daily) and/or caused distress or interfered with daily activities (rated once for each cycle assessed); all 14 items were rated on a 4-point scale (not at all, a little, quite a bit, very much). Diary cards were administered by the hospital for completion on days 1--21 of cycles 1, 5 and 8 and mailed by patients to CaCTUS. At 9, 12, 18 and 24 months post-randomisation the same diary card items concerning distress and interference of side effects were incorporated into the QL booklet.

In a separate but related initiative, patients who were disease-free and continuing in follow-up at 6 years were invited to participate in a cross-sectional QL assessment focusing on residual systemic therapy effects in the survivorship context (to be reported separately). Data from patients who also participated in the original QL sub-study were included in the longitudinal analyses reported here.

2.3. Endpoints {#s0035}
--------------

The co-primary endpoints were EORTC QLQ-C30 global health/QL and psychological distress (HADS anxiety and depression subscales). Secondary endpoints included other subscales and items of specific interest from the EORTC questionnaires (including fatigue, pain, nausea/vomiting and systemic side effect subscales) and patient diaries.

2.4. Scoring and statistical analysis {#s0040}
-------------------------------------

EORTC questionnaires were scored according to standard procedures [@b0125]. Change from baseline values on any subscale was considered clinically relevant with a difference of ⩾10 [@b0130] and statistically significant if *p* ⩽ 0.05 (primary endpoints) or *p* ⩽ 0.01 (all other endpoints).

Recommended threshold scores for HADS anxiety and depression were used: scores ⩾ 11 indicated probable case disorder, scores 8--10 indicated borderline disorder and scores \< 8 were considered normal. Prevalence rates refer to borderline and probable case categories combined.

The study design included at least 500 patients, with an approximate 5% attrition rate, providing 97% power to detect difference of 20% or more in any proportion (1% significance) and 78% power for differences of 15% or, alternatively, 90% power to detect a standardised difference of 0.35 (1% significance). Due to rapid accrual to the main trial the final size of the sample was larger than originally anticipated, increasing the power of comparisons.

Analyses comparing FEC-D to control were according to intention-to-treat, adjusted for centre's choice of standard control regimen. Dichotomised outcomes were adjusted for baseline score and analysed by logistic regression (with odds ratios (OR) reported). Subscale scores were compared between randomised groups using analysis of covariance with change from baseline adjusted for baseline scores. Mean differences in change from baseline (FEC-D − control) are reported with 95% (primary endpoints)/99% (secondary endpoints) confidence intervals. Categorised anxiety and depression subscale scores were compared using generalised ordinal logistic regression [@b0135]. Treatment side effects (diary card data) were analysed by Cochran--Mantel--Haenszel test (no baseline data were available for adjustment). Time points for formal analysis were cycle 8, and 9 and 24 months from randomisation. Generalised estimating equations were used for longitudinal analysis. These models (not shown) gave similar results to single time point analyses. Subgroup analyses by centre's choice of control regimen (i.e. comparing FEC-D to FEC and FEC-D to E-CMF), menopausal status and sensitivity analyses assessing robustness to missing data and time windows of questionnaire response and excluding questionnaires completed after a disease event (not shown) were consistent with the main analysis results unless otherwise stated. Analyses were conducted in STATA v10.1.

2.5. Study oversight {#s0045}
--------------------

TACT (ISRCTN79718493), including the QL sub-study, was approved by the national South East Multi-Research Ethics Committee (MREC00/1/59) and the local ethics committees of all participating centres. The Cancer Research UK funded Clinical Trials and Statistics Unit (ICR-CTSU) at The Institute of Cancer Research had overall responsibility for trial co-ordination and undertook all statistical analyses; a central QL co-ordinator at CaCTUS was responsible for QL project management.

2.6. Role of the funding sources {#s0050}
--------------------------------

TACT was funded by Cancer Research UK (C1491/A2645, C1491/A4129, C1491/A6852, C1491/A9895) and educational grants from collaborating pharmaceutical companies: Sanofi-Aventis, Pfizer and Roche. Funders had no role in study design, collection, analysis, interpretation of data, or writing of the report. All authors had access to study data and the corresponding author had final responsibility for the decision to submit for publication.

3. Results {#s0055}
==========

Between July 2001 and August 2002, 830 women (415 FEC-D; 415 Control), from 44 UK centres, entered the QL sub-study ([Fig. 1](#f0005){ref-type="fig"}). 797/830 (96.0%) patients returned a baseline questionnaire and form the primary analysis population. Questionnaire return rates were high ([Fig. 1](#f0005){ref-type="fig"}) although decreased over the 2 years to 78.9% (control) and 79.1% (FEC-D). Diary card return rate during treatment was 57.8%, 58.3% and 55.3% for cycles 1, 5 and 8, respectively increasing to 78.9% at 9 months and 69.9% at 2 years. At 6 years, 349/538 (64.9%) patients (171 control; 178 FEC-D) completed QL booklets.

Baseline characteristics of QL patients ([Table 1](#t0005){ref-type="table"}) were similar to those of the 540 TACT patients at centres participating in the QL substudy who were ineligible, not approached or chose not to enter the QL substudy.

3.1. Global health/QL and psychological distress {#s0060}
------------------------------------------------

Patients' ratings showed a clinically relevant impairment of global health/QL during treatment, which was statistically significantly worse for the FEC-D group compared with controls at cycle 8 (mean difference in change from baseline: −6.32 (95% CI: −9.42 to −3.23), *p* \< 0.0001) ([Fig. 2](#f0010){ref-type="fig"}). This difference was consistent when FEC-D was compared with each control regimen separately (test for heterogeneity: *p* = 0.95). Recovery to baseline levels occurred for women in both regimens by 12 months and scores were similar and unchanged from baseline at 2 and 6 years ([Fig. 2](#f0010){ref-type="fig"})*.* Anxiety prevalence was greatest (44.3%) pre-treatment reducing over time to affect 30--35% women post-treatment with no significant differences between the regimens ([Fig. 3](#f0015){ref-type="fig"}). In contrast, depression affected 11.9% women at baseline but increased during treatment ([Fig. 3](#f0015){ref-type="fig"}) and was significantly worse for FEC-D patients compared with controls at cycle 8 (30.6% versus 23.9%; OR = 1.63 (1.11--2.39), *p* = 0.01). No differences were seen at later time points and there was no evidence of heterogeneity by control regimen. The prevalence of anxiety remained greater than depression throughout follow-up.

3.2. General treatment side effects {#s0065}
-----------------------------------

Patients' ratings of general treatment toxicity are reflected in the BR23 systemic side effects subscale and the QLQC30 fatigue, pain and nausea and vomiting symptom subscales ([Fig. 2](#f0010){ref-type="fig"}). A clinically relevant increase in systemic side effects was shown for control and FEC-D regimens from baseline to mid treatment. At cycle 8 this increase was significantly greater for FEC-D patients (mean difference in change from baseline 4.02, 99% CI: 0.33--7.72, *p* = 0.005) with no evidence of heterogeneity by control regimen (*p* = 0.87). Fatigue and pain were also worse in FEC-D patients at cycle 8 whilst control patients reported more nausea and vomiting ([Fig. 2](#f0010){ref-type="fig"}).

In terms of individual systemic side effects, at cycle 8, the odds of rating BR23 symptom items as 'quite a bit' or 'very much' were significantly greater in the FEC-D group for different taste and sore/watery eyes; odds of reporting hot flushes and dry mouth were significantly greater in control patients ([web appendix Table 1a and b](#s0110){ref-type="sec"}). All systemic effects except dry mouth reduced similarly in both treatment groups over follow-up to 24 months but did not recover to baseline levels. Odds of reporting dry mouth at 2 years were greater in control than FEC-D patients (OR = 0.34 (0.13--0.86), *p* = 0.003). Moderate or marked hot flushes were prevalent and persistent for patients in both regimens, increasing from 18.4% FEC-D and 12.5% control at baseline to 38.9% and 46.7% respectively at cycle 8; levels peaked at 9 months (58.2% and 48.6% respectively) affecting around 50% women to 2 years and were reported by more than a quarter of women at 6 years ([web appendix Table 1a](#s0110){ref-type="sec"}).

3.3. Pattern of QL changes over time {#s0070}
------------------------------------

Patients' self-reports of other QL domains mirrored those of their side effects, with clinically relevant worsening of multiple QL domains for both FEC-D and control regimens ([Fig. 2](#f0010){ref-type="fig"}). Statistically significant differences in subscale change scores between the regimens at cycle 8 indicated more severe side effects and functional disruption in the FEC-D regimen ([Fig. 2](#f0010){ref-type="fig"}) but differences were not considered clinically relevant. Most QL subscale scores improved post treatment to near baseline values, although women's ratings of their body image and sexual functioning took longer to resolve. No further changes were observed at 6 years.

3.4. Diary cards: impact of treatment on side effects {#s0075}
-----------------------------------------------------

Patients' diary ratings provided new insight into the prevalence and impact of a large range of specific treatment-related side effects ([Fig. 4](#f0020){ref-type="fig"}, [Tables 2 and 3](#t0010 t0015){ref-type="table"}). First, a wide variability in the proportion of women rating 'quite a bit' or 'very much' experience of individual side effects was observed, with the highest rates for tiredness and the lowest for diarrhoea. Second, the pattern of side effect frequency over each cycle was similar for each treatment group ([Fig. 4](#f0020){ref-type="fig"}) but significantly more patients in the FEC-D group experienced moderate or marked effects compared with controls. Third, novel observations showed that at cycle 8 the FEC-D regimen accounted for significantly increased distress and/or interference with activities, rated by patients as 'quite a bit' or 'very much' for eight side effects (skin changes, tingling hands/feet, tiredness, breathlessness, swollen hands/feet, nail changes, muscle/joint pains and painful/gritty eyes); women in the control group rated significantly worse distress and/or interference in activities from nausea and vomiting ([Tables 2 and 3](#t0010 t0015){ref-type="table"}). Subgroup analyses by centre's choice of control regimen had minimal effect on overall findings (see [web appendix Tables 2a,b and 3a,b](#s0110){ref-type="sec"}); the only statistically significant interaction between randomised treatment and centre's choice of control regimen was for diarrhoea at cycle 8 (FEC-D more distress than FEC but FEC-D less distress than E-CMF).

Peak severity of side effects was mainly at cycle 8 but earlier for sore mouth, nausea and mouth ulcers. Of note, there was persistence of some distress and or interference with activities beyond completion of chemotherapy. At 9 months significantly more distress/interference was observed due to tingling hands/feet and nail changes in the FEC-D group and to tiredness in the control group. Differences between the regimens resolved by 24 months. Centre's choice of control regimen was not a significant factor in analyses at 9 and 24 months.

4. Discussion {#s0080}
=============

The findings of this large study of QL and toxicity provide clear evidence of women's experience of greater toxicity and disruption to diverse aspects of their QL over many months from taxane-containing treatment compared to standard adjuvant chemotherapy. Whilst established QL subscales provide broad coverage, details of the impact of toxicity are better reflected using the diary card approach. These results build usefully on the well-established but more limited reporting of adverse effects in other such clinical trials [@b0015; @b0020; @b0025; @b0030; @b0035; @b0040; @b0045; @b0050], TACT patients were able to report not only the severity and duration of side effects, but also the unique distress and disruption to daily life that each symptom caused. For instance, nail changes, swollen and/or tingling hands or feet may be regarded clinically as manageable or of nuisance value, but were not only more prevalent, and distressing but also interfered more with daily life in women receiving FEC-D than those treated with standard regimens. This supports evidence from smaller studies exploring more specific taxane toxicities [@b0020; @b0140; @b0145; @b0150], and may help explain delayed emotional recovery, reduced compliance or early discontinuation of taxane containing chemotherapy [@b0155; @b0160]. The introduction of TACT diary cards gave unique insights into the impact of adjuvant chemotherapy; to our knowledge similar findings have not previously been reported in an adjuvant breast cancer clinical trial.

Assessment of multiple QL domains highlighted the social, psychological and physical reality of undergoing adjuvant chemotherapy, with worsening and improvement in these domains mirroring that of toxicity. Most functional and psychosocial domains as well as side effects reduced substantially after the end of treatment. Exceptions were slow recovery of body image and sexual function and persistent tiredness and joint pains, irrespective of regimen, possibly secondary to changes in hormonal status. The onset of a menopause after chemotherapy is an important survivorship concern [@b0165], whilst younger patients report both more menopausal concerns [@b0170] and greater concerns about fertility than age matched controls [@b0175]. Women in the TACT trial who underwent a menopausal transition may have experienced such concerns and so clinical teams need to distinguish QL issues due to these problems in order to give appropriate support and advice.

It is implicit in QL evaluation that findings will be taken into account in trial outcomes and translated into clinical practice. Together with the TACT clinical results [@b0010] these findings can aid clinicians' discussion with patients. The indication to use taxanes in combination with trastuzumab or similar agents means that a substantial minority of women will be exposed to this increased toxicity. Moreover, appropriate support and advice are needed to mitigate distress and optimise side effect management. Similar considerations exist for women with metastatic disease where the burden of toxicity must be balanced against treatment efficacy in the palliative setting.

Our findings were consistent across QL domains but interpretation may be affected by several factors. Eighty-eight (21.2%) controls and 66 (15.9%) FEC-D patients stopped treatment early; the majority of those in the FEC-D group received at least one taxane cycle but had higher systemic side effect scores than those completing treatment. Control group patients stopping early had slightly lower side effect scores than those completing treatment but differences between these subgroups were not clinically relevant. Diary cards discriminated well between the treatment regimens but completion rates were lower during treatment compared with follow-up: administrative problems may have contributed. It should be noted that statistically significant differences between the experimental and control regimens may not necessarily be clinically relevant. Strengths of this study include the large sample size and the low level of attrition together with detailed and novel reporting of treatment side effects.

It has been reported that doctors 'underestimate' patients' symptoms and distress and therefore patient reported outcomes are more 'accurate', however medical assessments and patients' ratings are drawn from different contexts and are not interchangeable [@b0055; @b0060; @b0180; @b0185]. Biomedical and psychosocial perspectives are complementary [@b0190; @b0195; @b0200], both providing valuable insights into the treatment experience. This is particularly relevant when considering regimens where the trade-off between toxicity and benefit is small, uncertain or absent. Therefore equal emphasis to the patients' and clinicians' perspectives can provide optimal care for women undergoing adjuvant chemotherapy. As indications for the use of taxanes in the management of early breast cancer evolve the trade-off between clinical benefit and QL will need to be reassessed both in randomised controlled trials and in the decision making process for individual patients.
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![Change from baseline in EORTC QLQ-C30 and BR23 functional and symptom subscales scores at each time point. Text shows mean difference in change from baseline^†^ (FEC-D minus control, with confidence interval^‡^ and p value) at cycle 8. Red = FEC-D, blue = control. ^†^Change from baseline scores are adjusted for baseline score, chosen control and randomised treatment group using an analysis of covariance (ANCOVA) model. ^∗^Positive change from baseline indicates a worsening of symptoms; otherwise deterioration in function is shown by a negative change score. ^‡^95% confidence interval is given for the primary endpoint of global health/QL, 99% confidence intervals for all other subscales. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)](gr2){#f0010}

![HADS anxiety and depression ratings (probable case disorder, borderline disorder, normal) by regimen at each time point. Graph shows predicted probabilities from generalised ordinal logistic regression models adjusting for baseline score, chosen control and randomised treatment. Number of observations at each time point are given in parentheses.](gr3){#f0015}

![Diary card: Proportion experiencing side effect 'quite a bit' or 'very much' during treatment by regimen. *P*-values compare area under the curve by Mann--Whitney *U* test. Note scale of vertical axis differs on each row.](gr4){#f0020}

###### 

Baseline characteristics by randomised group.

                                                                      Control (*N* = 415)   FEC-D (*N* = 415)   Total (*N* = 830)                         
  ----------------------------------- ------------------------------- --------------------- ------------------- ------------------- -------------- ------ --------------
  Control arm                         FEC                             268                   64.6                271                 65.3           539    64.9
  E-CMF                               147                             35.4                  144                 34.7                291            35.1   
                                                                                                                                                          
  Age (years)                         Mean (SD)                       47.7                  (8.7)               49.5                (8.4)          48.6   (8.6)
  \<40                                96                              23.1                  65                  15.7                161            19.4   
  40--49                              145                             34.9                  131                 31.6                276            33.3   
  50--59                              143                             34.5                  176                 42.4                319            38.4   
  60+                                 31                              7.5                   43                  10.4                74             8.9    
                                                                                                                                                          
  Menopausal status                   Post-menopasual                 187                   45.1                218                 52.5           405    48.8
  Not menopausal (i.e. pre or peri)   228                             54.9                  197                 47.5                425            51.2   
                                                                                                                                                          
  Ethnicity                           White                           391                   94.2                394                 94.9           785    94.6
  Other                               15                              3.6                   16                  3.9                 31             3.7    
  Not known                           9                               2.2                   7                   1.7                 16             1.9    
                                                                                                                                                          
  Type of surgery                     Mastectomy                      210                   50.6                225                 54.2           435    52.4
  Local excision                      205                             49.4                  190                 45.8                395            47.6   
                                                                                                                                                          
  Radiotherapy given                  Yes                             357                   86.0                354                 85.3           711    85.7
  No                                  44                              10.6                  39                  9.4                 83             10.0   
  Not known                           14                              3.4                   22                  5.3                 36             4.3    
                                                                                                                                                          
  Nodal status                        Positive                        332                   80.0                333                 80.2           665    80.1
  Negative                            83                              20.0                  82                  19.8                165            19.9   
                                                                                                                                                          
  Tumour grade                        I                               19                    4.6                 21                  5.1            40     4.8
  II                                  149                             35.9                  140                 33.7                289            34.8   
  III                                 246                             59.3                  251                 60.5                497            59.9   
  Not known                           1                               0.2                   3                   0.7                 4              0.5    
                                                                                                                                                          
  Tumour size                         \<2 cm                          227                   54.7                226                 54.5           453    54.6
  2--5 cm                             143                             34.5                  146                 35.2                289            34.8   
  \>5 cm                              45                              10.8                  43                  10.4                88             10.6   
  Not known                           0                               0.0                   0                   0.0                 0              0.0    
                                                                                                                                                          
  Oestrogen receptor (ER) status      Positive                        279                   67.2                275                 66.3           554    66.7
  Negative                            136                             32.8                  140                 33.7                276            33.3   
                                                                                                                                                          
  Progesterone receptor status        Positive                        99                    23.9                93                  22.4           192    23.1
  Negative                            96                              23.1                  94                  22.7                190            22.9   
  Not known                           220                             53.0                  228                 54.9                448            54.0   
                                                                                                                                                          
  Endocrine therapy received          None (ER negative)              136                   32.8                140                 33.7           276    33.3
  Tamoxifen only                      173                             41.7                  186                 44.8                359            43.3   
  Aromatase inhibitor (AI) only       18                              4.3                   6                   1.4                 24             2.9    
  Tamoxifen and switched to AI        78                              18.8                  78                  18.8                156            18.8   
  None (ER positive)                  10                              2.4                   5                   1.2                 15             1.8    
                                                                                                                                                          
  HER2 status                         Negative                        290                   69.9                281                 67.7           571    68.8
  Positive                            80                              19.3                  91                  21.9                171            20.6   
   Positive and received Herceptin    7                               1.7                   6                   1.4                 13             1.6    
  Not known                           45                              10.8                  43                  10.4                88             10.6   
                                                                                                                                                          
  Combined ER/HER2 status             ER+/HER2+                       44                    10.6                47                  11.3           91     11.0
  ER+/HER2−                           205                             49.4                  198                 47.7                403            48.6   
  ER+/HER2 not known                  30                              7.2                   30                  7.2                 60             7.2    
  ER-/HER2+                           36                              8.7                   44                  10.6                80             9.6    
  ER-/HER2−                           85                              20.5                  83                  20.0                168            20.2   
  ER-/HER2 not known                  15                              3.6                   13                  3.1                 28             3.4    
                                                                                                                                                          
  EORTC QLQ-C30                       Global health/QL median (IQR)   75                    (58.3, 83.3)        75                  (58.3, 83.3)   75     (58.3, 83.3)
                                                                                                                                                          
  HADS anxiety                        Normal (\<8)                    222                   53.5                233                 56.1           455    54.8
  Borderline disorder (8--10)         86                              20.7                  83                  20.0                169            20.4   
  Probable case disorder (⩾11)        105                             25.3                  94                  22.7                199            24.0   
  Not known                           2                               0.5                   5                   1.2                 7              0.8    
                                                                                                                                                          
  HADS depression                     Normal (\<8)                    359                   86.5                364                 87.7           723    87.1
  Borderline disorder (8--10)         37                              8.9                   32                  7.7                 69             8.3    
  Probable case disorder (⩾11)        16                              3.9                   14                  3.4                 30             3.6    
  Not known                           3                               0.7                   5                   1.2                 8              1.0    

###### 

Diary card ratings of side effect experience, distress and interference with activities: proportion rating as 'quite a bit'/'very much'.

  Side Effect                                                         Cycle 1   Cycle 5   Cycle 8   9 Months   12 Months   18 Months   24 Months                                                                                                                                                                                       
  ---------------------------------------------------- -------------- --------- --------- --------- ---------- ----------- ----------- ----------- -------- -------- -------- -------- -------- -------- -------- -------- -------- -------- -------- -------- -------- -------- -------- -------- -------- -------- -------- -------- --------
  Nausea                                               Experience     108       (47.8)    134       (52.8)     103         (45.6)      41          (15.9)   79       (36.1)   35       (14.6)                                                                                                                                          
                                                       Distress       60        (26.5)    79        (31.1)     58          (25.7)      20          (7.8)    39       (17.8)   15       (6.3)    12       (3.7)    15       (4.5)    9        (2.9)    6        (1.8)    6        (2.0)    3        (1.0)    1        (0.3)    6        (2.0)
                                                       Interference   63        (27.9)    75        (29.5)     53          (23.5)      17          (6.6)    35       (16.0)   14       (5.8)    9        (2.8)    7        (2.1)    6        (1.9)    3        (0.9)    6        (2.0)    4        (1.3)    1        (0.3)    4        (1.4)
                                                                                                                                                                                                                                                                                                                                       
  Vomiting                                             Experience     44        (19.5)    73        (28.7)     36          (15.9)      22          (8.5)    33       (15.1)   11       (4.6)                                                                                                                                           
                                                       Distress       34        (15.0)    58        (22.8)     29          (12.8)      10          (3.9)    18       (8.2)    4        (1.7)    4        (1.2)    2        (0.6)    3        (1.0)    2        (0.6)    2        (0.7)    2        (0.6)    0        \(0\)    2        (0.7)
                                                       Interference   36        (15.9)    55        (21.7)     23          (10.2)      7           (2.7)    19       (8.7)    4        (1.7)    5        (1.6)    1        (0.3)    4        (1.3)    1        (0.3)    3        (1.0)    1        (0.3)    1        (0.3)    4        (1.4)
                                                                                                                                                                                                                                                                                                                                       
  Skin                                                 Experience     26        (11.5)    24        (9.4)      22          (9.7)       63          (24.4)   18       (8.2)    67       (27.9)                                                                                                                                          
                                                       Distress       5         (2.2)     7         (2.8)      6           (2.7)       30          (11.6)   7        (3.2)    26       (10.8)   30       (9.3)    37       (11.1)   14       (4.5)    18       (5.3)    14       (4.8)    14       (4.5)    17       (5.9)    13       (4.4)
                                                       Interference   1         (0.4)     5         (2.0)      2           (0.9)       14          (5.4)    5        (2.3)    4        (1.7)    8        (2.5)    11       (3.3)    4        (1.3)    5        (1.5)    4        (1.4)    5        (1.6)    8        (2.8)    6        (2.0)
                                                                                                                                                                                                                                                                                                                                       
  Tingling/numb hands/feet                             Experience     12        (5.3)     10        (3.9)      12          (5.3)       76          (29.5)   17       (7.8)    100      (41.7)                                                                                                                                          
  Distress                                             4              (1.8)     3         (1.2)     5          (2.2)       29          (11.2)      10       (4.6)    56       (23.3)   29       (9.0)    75       (22.5)   33       (10.5)   45       (13.2)   26       (8.9)    28       (9.0)    25       (8.7)    27       (9.2)    
                                                       Interference   1         (0.4)     0         \(0\)      4           (1.8)       26          (10.1)   6        (2.7)    32       (13.3)   20       (6.2)    34       (10.2)   18       (5.7)    22       (6.4)    13       (4.4)    13       (4.2)    10       (3.5)    12       (4.1)
                                                                                                                                                                                                                                                                                                                                       
  Tiredness                                            Experience     140       (61.9)    182       (71.7)     165         \(73\)      216         (83.7)   161      (73.5)   207      (86.3)                                                                                                                                          
                                                       Distress       55        (24.3)    79        (31.1)     83          (36.7)      128         (49.6)   80       (36.5)   114      (47.5)   94       (29.3)   83       (24.9)   64       (20.4)   57       (16.7)   61       (20.8)   59       \(19\)   54       (18.8)   46       (15.7)
                                                       Interference   78        (34.5)    102       (40.2)     106         (46.9)      147         (57.0)   85       (38.8)   129      (53.8)   94       (29.3)   69       (20.7)   58       (18.5)   44       (12.9)   48       (16.4)   37       (11.9)   44       (15.3)   43       (14.7)
                                                                                                                                                                                                                                                                                                                                       
  Diarrhoea                                            Experience     26        (11.5)    31        (12.2)     35          (15.5)      74          (28.7)   41       (18.7)   51       (21.3)                                                                                                                                          
  Distress                                             10             (4.4)     11        (4.3)     10         (4.4)       40          (15.5)      19       (8.7)    17       (7.1)    9        (2.8)    10       (3.0)    6        (1.9)    6        (1.8)    6        (2.0)    9        (2.9)    11       (3.8)    5        (1.7)    
                                                       Interference   5         (2.2)     8         (3.1)      10          (4.4)       31          (12.0)   16       (7.3)    12       (5.0)    4        (1.2)    6        (1.8)    3        (1.0)    2        (0.6)    5        (1.7)    6        (1.9)    7        (2.4)    4        (1.4)
                                                                                                                                                                                                                                                                                                                                       
  Constipation                                         Experience     62        (27.4)    86        (33.9)     56          (24.8)      64          (24.8)   56       (25.6)   53       (22.1)                                                                                                                                          
  Distress                                             25             (11.1)    35        (13.8)    28         (12.4)      32          (12.4)      27       (12.3)   24       (10.0)   16       (5.0)    16       (4.8)    11       (3.5)    5        (1.5)    9        (3.1)    10       (3.2)    16       (5.6)    5        (1.7)    
                                                       Interference   11        (4.9)     21        (8.3)      16          (7.1)       21          (8.1)    9        (4.1)    13       (5.4)    7        (2.2)    7        (2.1)    4        (1.3)    4        (1.2)    5        (1.7)    6        (1.9)    9        (3.1)    2        (0.7)
                                                                                                                                                                                                                                                                                                                                       
  Sore mouth                                           Experience     31        (13.7)    37        (14.6)     49          (21.7)      144         (55.8)   58       (26.5)   87       (36.3)                                                                                                                                          
  Distress                                             18             (8.0)     20        (7.9)     29         (12.8)      100         (38.8)      31       (14.2)   53       (22.1)   8        (2.5)    20       (6.0)    5        (1.6)    9        (2.6)    7        (2.4)    7        (2.3)    10       (3.5)    7        (2.4)    
                                                       Interference   6         (2.7)     12        (4.7)      24          (10.6)      61          (23.6)   16       (7.3)    29       (12.1)   9        (2.8)    12       (3.6)    4        (1.3)    5        (1.5)    4        (1.4)    4        (1.3)    6        (2.1)    5        (1.7)
                                                                                                                                                                                                                                                                                                                                       
  Mouth ulcers                                         Experience     12        (5.3)     18        (7.1)      28          (12.4)      59          (22.9)   36       (16.4)   35       (14.6)                                                                                                                                          
  Distress                                             8              (3.5)     15        (5.9)     17         (7.5)       50          (19.4)      27       (12.3)   29       (12.1)   4        (1.2)    14       (4.2)    3        (1.0)    6        (1.8)    6        (2.0)    5        (1.6)    5        (1.7)    7        (2.4)    
                                                       Interference   1         (0.4)     8         (3.1)      12          (5.3)       32          (12.4)   17       (7.8)    16       (6.7)    7        (2.2)    11       (3.3)    3        (1.0)    5        (1.5)    6        (2.0)    4        (1.3)    2        (0.7)    4        (1.4)
                                                                                                                                                                                                                                                                                                                                       
  Breathlessness                                       Experience     15        (6.6)     22        (8.7)      38          (16.8)      53          (20.5)   61       (27.9)   72       (30.0)                                                                                                                                          
  Distress                                             11             (4.9)     15        (5.9)     27         (11.9)      41          (15.9)      31       (14.2)   54       (22.5)   27       (8.4)    25       (7.5)    25       (8.0)    17       (5.0)    19       (6.5)    13       (4.2)    18       (6.3)    16       (5.5)    
                                                       Interference   10        (4.4)     17        (6.7)      28          (12.4)      40          (15.5)   37       (16.9)   57       (23.8)   28       (8.7)    23       (6.9)    23       (7.3)    19       (5.6)    15       (5.1)    11       (3.5)    19       (6.6)    14       (4.8)
                                                                                                                                                                                                                                                                                                                                       
  Swollen hands/feet                                   Experience     6         (2.7)     11        (4.3)      27          (11.9)      49          (19.0)   31       (14.2)   82       (34.2)                                                                                                                                          
  Distress                                             3              (1.3)     2         (0.8)     9          (4.0)       19          (7.4)       13       (5.9)    39       (16.3)   37       (11.5)   54       (16.2)   37       (11.8)   33       (9.6)    22       (7.5)    32       (10.3)   23       (8.0)    19       (6.5)    
                                                       Interference   1         (0.4)     3         (1.2)      9           (4.0)       14          (5.4)    12       (5.5)    28       (11.7)   21       (6.5)    33       (9.9)    26       (8.3)    17       (5.0)    16       (5.5)    19       (6.1)    17       (5.9)    10       (3.4)
                                                                                                                                                                                                                                                                                                                                       
  Nail changes                                         Experience     3         (1.3)     5         (2.0)      20          (8.8)       54          (20.9)   26       (11.9)   120      (50.0)                                                                                                                                          
  Distress                                             1              (0.4)     0         \(0\)     6          (2.7)       31          (12.0)      13       (5.9)    69       (28.7)   36       (11.2)   93       (27.8)   16       (5.1)    30       (8.8)    16       (5.5)    16       (5.1)    16       (5.6)    15       (5.1)    
                                                       Interference   0         \(0\)     0         \(0\)      1           (0.4)       20          (7.8)    4        (1.8)    33       (13.8)   11       (3.4)    32       (9.6)    1        (0.3)    11       (3.2)    8        (2.7)    9        (2.9)    11       (3.8)    5        (1.7)
                                                                                                                                                                                                                                                                                                                                       
  Lack of appetite                                     Experience     86        (38.1)    113       (44.5)     68          (30.1)      94          (36.4)   59       (26.9)   70       (29.2)                                                                                                                                          
  Distress                                             20             (8.8)     18        (7.1)     19         (8.4)       20          (7.8)       18       (8.2)    20       (8.3)    15       (4.7)    16       (4.8)    11       (3.5)    7        (2.0)    4        (1.4)    10       (3.2)    7        (2.4)    7        (2.4)    
                                                       Interference   15        (6.6)     14        (5.5)      16          (7.1)       15          (5.8)    6        (2.7)    9        (3.8)    13       (4.0)    6        (1.8)    8        (2.5)    5        (1.5)    3        (1.0)    3        (1.0)    4        (1.4)    5        (1.7)
                                                                                                                                                                                                                                                                                                                                       
  Muscle/joint pain[⁎](#tblfn1){ref-type="table-fn"}   Experience     18        (19.1)    14        (15.1)     42          (20.5)      165         (72.1)   61       (28.0)   142      (59.2)                                                                                                                                          
  Distress                                             6              (6.4)     6         (6.5)     19         (9.3)       125         (54.6)      31       (14.2)   91       (37.9)   89       (27.7)   100      (29.9)   71       (22.6)   80       (23.4)   63       (21.5)   65       (20.9)   64       (22.3)   56       (19.1)   
                                                       Interference   8         (8.5)     7         (7.5)      21          (10.2)      118         (51.5)   29       (13.3)   83       (34.6)   69       (21.5)   60       (18.0)   53       (16.9)   51       (14.9)   43       (14.7)   40       (12.9)   49       (17.1)   34       (11.6)
                                                                                                                                                                                                                                                                                                                                       
  Painful/ gritty eyes                                 Experience     20        (8.8)     18        (7.1)      39          (17.3)      43          (16.7)   43       (19.6)   64       (26.7)                                                                                                                                          
  Distress                                             8              (3.5)     8         (3.1)     32         (14.2)      37          (14.3)      28       (12.8)   51       (21.3)   17       (5.3)    23       (6.9)    8        (2.5)    17       (5.0)    15       (5.1)    15       (4.8)    15       (5.2)    8        (2.7)    
  Interference                                         5              (2.2)     7         (2.8)     21         (9.3)       21          (8.1)       17       (7.8)    36       \(15\)   12       (3.7)    13       (3.9)    5        (1.6)    7        (2.0)    8        (2.7)    6        (1.9)    8        (2.8)    4        (1.4)    

The item on muscle/joint pain was added in November 2001 when this was identified as a relevant side effect. During treatment only, this item is summarised as % of non-missing, and was completed by (Control and FEC-D): cycle 1--94 and 93 patients; cycle 5--205 and 229 patients; cycle 8--218 and 240 patients.

###### 

Odds ratios (OR)[†](#tblfn2){ref-type="table-fn"} for diary card reports of side effect experience, distress and interference with activities as 'quite a bit' or 'very much'.

                                          Cycle 8         9 Months        24 Months                                                                                           
  -------------------------- ------------ --------------- --------------- ----------- --------------- ---------- ------------------------------------- --------------- ------ --
  Nausea                     Experience   0.30            (0.16, 0.56)    \<0.0001                                                                                            
  Distress                   0.30         (0.13, 0.70)    0.0001          1.22        (0.44, 3.36)    0.62       5.98                                  (0.36, 98.04)   0.06   
  Interference               0.32         (0.13, 0.76)    0.0004          0.75        (0.20, 2.80)    0.58       3.91                                  (0.22, 69.63)   0.19   
                                                                                                                                                                              
  Vomiting                   Experience   0.27            (0.10, 0.69)    0.0001                                                                                              
  Distress                   0.19         (0.05, 0.81)    0.001           0.48        (0.05, 4.42)    0.39       --[⁎](#tblfn3){ref-type="table-fn"}   (--, --)        0.16   
  Interference               0.18         (0.04, 0.76)    0.0005          0.19        (0.01, 3.18)    0.09       3.97                                  (0.22, 73.31)   0.19   
                                                                                                                                                                              
  Skin                       Experience   4.34            (2.02, 9.31)    \<0.0001                                                                                            
  Distress                   3.87         (1.24, 12.05)   0.001           1.21        (0.62, 2.36)    0.47       0.73                                  (0.27, 1.94)    0.4    
  Interference               0.77         (0.13, 4.45)    0.7             1.35        (0.40, 4.61)    0.52       0.72                                  (0.18, 2.98)    0.55   
                                                                                                                                                                              
  Tingling/numb hands/feet   Experience   8.76            (3.90, 19.66)   \<0.0001                                                                                            
  Distress                   7.01         (2.65, 18.52)   \<0.0001        2.89        (1.56, 5.34)    \<0.0001   1.07                                  (0.51, 2.25)    0.82   
  Interference               5.92         (1.78, 19.68)   \<0.0001        1.73        (0.81, 3.70)    0.06       1.17                                  (0.38, 3.61)    0.72   
                                                                                                                                                                              
  Tiredness                  Experience   2.40            (1.25, 4.61)    0.0004                                                                                              
  Distress                   1.73         (1.03, 2.90)    0.006           0.80        (0.50, 1.26)    0.2        0.80                                  (0.45, 1.42)    0.32   
  Interference               2.09         (1.23, 3.54)    0.0002          0.63        (0.39, 1.00)    0.01       0.94                                  (0.51, 1.71)    0.78   
                                                                                                                                                                              
  Diarrhoea                  Experience   1.19            (0.65, 2.17)    0.46                                                                                                
  Distress                   0.85         (0.35, 2.07)    0.64            1.05        (0.31, 3.54)    0.91       0.44                                  (0.11, 1.78)    0.12   
  Interference               0.71         (0.26, 1.93)    0.37            1.42        (0.26, 7.60)    0.59       0.55                                  (0.11, 2.80)    0.34   
                                                                                                                                                                              
  Constipation               Experience   0.83            (0.47, 1.47)    0.4                                                                                                 
  Distress                   0.79         (0.37, 1.71)    0.43            0.96        (0.38, 2.43)    0.9        0.29                                  (0.08, 1.13)    0.01   
  Interference               1.37         (0.43, 4.31)    0.48            0.94        (0.23, 3.83)    0.91       0.21                                  (0.03, 1.61)    0.03   
                                                                                                                                                                              
  Sore mouth                 Experience   1.60            (0.94, 2.71)    0.02                                                                                                
  Distress                   1.80         (0.94, 3.45)    0.02            2.51        (0.84, 7.52)    0.03       0.68                                  (0.19, 2.45)    0.44   
  Interference               1.85         (0.79, 4.35)    0.06            1.27        (0.41, 3.99)    0.58       0.81                                  (0.17, 3.93)    0.73   
                                                                                                                                                                              
  Mouth ulcers               Experience   0.88            (0.45, 1.72)    0.63                                                                                                
  Distress                   0.99         (0.47, 2.08)    0.98            3.51        (0.80, 15.47)   0.02       1.38                                  (0.30, 6.34)    0.58   
  Interference               0.87         (0.34, 2.22)    0.69            1.55        (0.44, 5.47)    0.37       1.94                                  (0.21, 18.32)   0.44   
                                                                                                                                                                              
  Breathlessness             Experience   1.11            (0.65, 1.90)    0.61                                                                                                
  Distress                   1.91         (0.99, 3.68)    0.009           0.88        (0.42, 1.86)    0.66       0.86                                  (0.35, 2.12)    0.66   
  Interference               1.68         (0.91, 3.12)    0.03            0.77        (0.36, 1.65)    0.38       0.70                                  (0.27, 1.77)    0.31   
                                                                                                                                                                              
  Swollen hands/feet         Experience   3.17            (1.69, 5.94)    \<0.0001                                                                                            
  Distress                   3.35         (1.39, 8.04)    0.0002          1.49        (0.82, 2.69)    0.08       0.79                                  (0.35, 1.83)    0.48   
  Interference               2.50         (0.98, 6.37)    0.009           1.55        (0.73, 3.30)    0.13       0.55                                  (0.19, 1.59)    0.14   
                                                                                                                                                                              
  Nail changes               Experience   7.58            (3.77, 15.26)   \<0.0001                                                                                            
  Distress                   7.36         (3.04, 17.79)   \<0.0001        3.06        (1.73, 5.39)    \<0.0001   0.91                                  (0.35, 2.37)    0.81   
  Interference               9.69         (2.32, 40.58)   \<0.0001        2.99        (1.18, 7.58)    0.001      0.43                                  (0.10, 1.77)    0.11   
                                                                                                                                                                              
  Lack of appetite           Experience   1.12            (0.65, 1.93)    0.59                                                                                                
  Distress                   1.02         (0.42, 2.45)    0.96            1.03        (0.40, 2.65)    0.94       0.98                                  (0.24, 3.94)    0.96   
  Interference               1.39         (0.35, 5.54)    0.54            0.44        (0.12, 1.59)    0.09       1.20                                  (0.21, 6.92)    0.78   
                                                                                                                                                                              
  Muscle/joint pain          Experience   3.80            (2.20, 6.57)    \<0.0001                                                                                            
  Distress                   4.04         (2.13, 7.68)    \<0.0001        1.11        (0.71, 1.73)    0.55       0.82                                  (0.48, 1.39)    0.33   
  Interference               3.77         (1.97, 7.21)    \<0.0001        0.80        (0.48, 1.34)    0.27       0.62                                  (0.33, 1.16)    0.05   
                                                                                                                                                                              
  Painful/gritty eyes        Experience   1.51            (0.84, 2.70)    0.07                                                                                                
  Distress                   1.93         (0.98, 3.80)    0.01            1.30        (0.56, 3.04)    0.42       0.51                                  (0.16, 1.61)    0.12   
  Interference               2.20         (0.98, 4.97)    0.01            1.03        (0.36, 2.95)    0.95       0.48                                  (0.10, 2.36)    0.22   

OR is for FEC-D versus control stratified by centre's choice of control regimen with *p*-values from a Cochran Mantel--Haenszel test.

OR not estimable as no patient in the control group reported symptom.

[^1]: See Supplementary data for list of contributers and Trial management group members.
